Single and multivariable analysis of association between exposure variables and anti-tuberculosis drug intolerance
| Risk factor | Drug intolerance | Single variable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|---|
| Yes (N=866) | No (N=66 681) | OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value | |
| Age (years) | ||||||
| 0–14 | 15 | 3710 | 0.46 (0.27 to 0.77) | 0.003 | 0.41 (0.24 to 0.70) | 0.001 |
| 15–44 | 362 | 40 918 | 1 | 1 | ||
| 45–64 | 234 | 12 837 | 2.06 (1.75 to 2.44) | <0.001 | 1.77 (1.49 to 2.11) | <0.001 |
| 65+ | 255 | 9211 | 3.13 (2.66 to 3.68) | <0.001 | 2.31 (1.93 to 2.78) | <0.001 |
| Sex | ||||||
| Male | 318 | 36 700 | 1 | 1 | ||
| Female | 543 | 29 825 | 2.10 (1.83 to 2.42) | <0.001 | 2.24 (1.95 to 2.59) | <0.001 |
| Year | ||||||
| 2001 | 58 | 4914 | 1 | <0.001* | 1 | |
| 2002 | 66 | 5545 | 1.00 (0.71 to 1.43) | 1.08 (0.76 to 1.55) | 0.66 | |
| 2003 | 38 | 5712 | 0.56 (0.37 to 0.85) | 0.61 (0.40 to 0.93) | 0.022 | |
| 2004 | 56 | 6048 | 0.78 (0.54 to 1.13) | 0.86 (0.59 to 1.25) | 0.43 | |
| 2005 | 64 | 6780 | 0.80 (0.56 to 1.14) | 0.96 (0.67 to 1.37) | 0.81 | |
| 2006 | 78 | 7265 | 0.91 (0.64 to 1.28) | 1.02 (0.72 to 1.45) | 0.91 | |
| 2007 | 84 | 7435 | 0.96 (0.68 to 1.34) | 1.12 (0.80 to 1.59) | 0.51 | |
| 2008 | 129 | 7638 | 1.43 (1.05 to 1.96) | 1.69 (1.23 to 2.33) | 0.001 | |
| 2009 | 158 | 7981 | 1.68 (1.23 to 2.27) | 1.91 (1.40 to 2.61) | <0.001 | |
| 2010 | 135 | 7363 | 1.55 (1.14 to 2.12) | 1.80 (1.32 to 2.48) | <0.001 | |
| Ethnic group | ||||||
| White | 341 | 13 845 | 2.19 (1.87 to 2.56) | <0.001 | 1.97 (1.67 to 2.33) | <0.001 |
| Black Caribbean | 9 | 1633 | 0.49 (0.25 to 0.95) | 0.036 | 0.55 (0.28 to 1.07) | |
| Black African | 109 | 14 826 | 0.65 (0.52 to 0.82) | <0.001 | 0.80 (0.64 to 1.01) | 0.078 |
| Indian/Pakistani/Bangladeshi | 298 | 26 520 | 1 | 1 | 0.058 | |
| Other | 82 | 7944 | 0.92 (0.72 to 1.18) | 0.50 | 1.04 (0.79 to 1.52) | 0.59 |
| UK-born | ||||||
| No | 469 | 44 917 | 1 | |||
| Yes | 320 | 16 968 | 1.81 (1.57 to 2.09) | <0.001 | ||
| Site of disease | ||||||
| Pulmonary | 395 | 30 612 | 1 | |||
| Extrapulmonary | 394 | 29 857 | 1.02 (0.89 to 1.18) | 0.75 | ||
| Both | 73 | 5995 | 0.94 (0.73 to 1.21) | 0.65 | ||
| Neither recorded | 4 | 217 | 1.43 (0.53 to 3.86) | 0.48 | ||
| Previous diagnosis | ||||||
| No | 676 | 50 609 | 1 | |||
| Yes | 85 | 4540 | 1.40 (1.12 to 1.76) | 0.004 | ||
| Previous treatment | ||||||
| No | 16 | 426 | 1 | |||
| Yes | 36 | 2347 | 0.41 (0.22 to 0.74) | 0.003 | ||
| Resistance to INH, PZA or EMB | ||||||
| No | 450 | 35 235 | 1 | |||
| Yes | 35 | 2354 | 1.16 (0.82 to 1.65) | 0.39 | ||
| Sputum smear positive | ||||||
| No | 212 | 16 382 | 1.19 (0.96 to 1.47) | 0.11 | ||
| Yes | 147 | 13 505 | 1 | |||
*p trend.
EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide.